Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply

Nitin Jain; Varsha Gandhi; William Wierda

doi:10.1056/NEJMc1908754

Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply

Nitin Jain, Varsha Gandhi, William Wierda

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	789
Number of pages	1
Journal	The New England journal of medicine
Volume	381
Issue number	8
DOIs	https://doi.org/10.1056/NEJMc1908754
State	Published - Aug 22 2019

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMc1908754

Cite this

@article{c0ec34188c3444b1b62d9f7fd1e3347d,

title = "Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply",

author = "Nitin Jain and Varsha Gandhi and William Wierda",

year = "2019",

month = aug,

day = "22",

doi = "10.1056/NEJMc1908754",

language = "English (US)",

volume = "381",

pages = "789",

journal = "The New England journal of medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "8",

}

TY - JOUR

T1 - Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply

AU - Jain, Nitin

AU - Gandhi, Varsha

AU - Wierda, William

PY - 2019/8/22

Y1 - 2019/8/22

UR - http://www.scopus.com/inward/record.url?scp=85071566385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071566385&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1908754

DO - 10.1056/NEJMc1908754

M3 - Letter

C2 - 31433937

AN - SCOPUS:85071566385

SN - 0028-4793

VL - 381

SP - 789

JO - The New England journal of medicine

JF - The New England journal of medicine

IS - 8

ER -

Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this